|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,032.00 DKK | -1.45% |
|
+0.05% | +36.15% |
| 12-04 | Genmab A/S Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 09:45 AM | |
| 12-04 | Genmab Closes $2.5 Billion Senior Notes Offering | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 10.11B | 8.48B | 14.6B | 16.47B | 21.53B | |||||
Total Revenues | 10.11B | 8.48B | 14.6B | 16.47B | 21.53B | |||||
Cost of Goods Sold, Total | - | - | - | 226M | 985M | |||||
Gross Profit | 10.11B | 8.48B | 14.6B | 16.25B | 20.54B | |||||
Selling General & Admin Expenses, Total | 661M | 1.28B | 2.68B | 3.3B | 3.79B | |||||
R&D Expenses | 3.12B | 4.18B | 5.52B | 7.63B | 9.67B | |||||
Other Operating Expenses, Total | 3.78B | 5.46B | 8.2B | 10.93B | 13.46B | |||||
Operating Income | 6.34B | 3.02B | 6.4B | 5.32B | 7.08B | |||||
Interest Expense, Total | -10M | -13M | -21M | -27M | -120M | |||||
Interest And Investment Income | 184M | 197M | 324M | 939M | 995M | |||||
Net Interest Expenses | 174M | 184M | 303M | 912M | 875M | |||||
Currency Exchange Gains (Loss) | -1.46B | 1.47B | 1.03B | -889M | 1.34B | |||||
Other Non Operating Income (Expenses) | - | - | - | - | - | |||||
EBT, Excl. Unusual Items | 5.05B | 4.67B | 7.73B | 5.34B | 9.29B | |||||
Merger & Related Restructuring Charges | - | - | - | - | -300M | |||||
Gain (Loss) On Sale Of Investments | 873M | -689M | -659M | 293M | 247M | |||||
Asset Writedown | -22M | - | -38M | - | -76M | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | 5.9B | 3.98B | 7.04B | 5.64B | 9.16B | |||||
Income Tax Expense | 1.15B | 975M | 1.51B | 1.28B | 1.32B | |||||
Earnings From Continuing Operations | 4.76B | 3.01B | 5.52B | 4.35B | 7.84B | |||||
Net Income to Company | 4.76B | 3.01B | 5.52B | 4.35B | 7.84B | |||||
Net Income - (IS) | 4.76B | 3.01B | 5.52B | 4.35B | 7.84B | |||||
Net Income to Common Incl Extra Items | 4.76B | 3.01B | 5.52B | 4.35B | 7.84B | |||||
Net Income to Common Excl. Extra Items | 4.76B | 3.01B | 5.52B | 4.35B | 7.84B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 73 | 46 | 84.45 | 66.64 | 122.21 | |||||
Basic EPS - Continuing Operations | 73 | 46 | 84.45 | 66.64 | 122.21 | |||||
Basic Weighted Average Shares Outstanding | 65.18M | 65.4M | 65.39M | 65.31M | 64.19M | |||||
Net EPS - Diluted | 72.21 | 45.54 | 83.65 | 66.02 | 121.36 | |||||
Diluted EPS - Continuing Operations | 72.21 | 45.54 | 83.65 | 66.02 | 121.36 | |||||
Diluted Weighted Average Shares Outstanding | 65.89M | 66.05M | 66.01M | 65.91M | 64.63M | |||||
Normalized Basic EPS | 48.45 | 44.65 | 73.91 | 51.14 | 90.49 | |||||
Normalized Diluted EPS | 47.93 | 44.21 | 73.21 | 50.67 | 89.86 | |||||
American Depositary Receipts Ratio (ADR) | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |||||
Supplemental Items | ||||||||||
EBITDA | 6.56B | 3.27B | 6.72B | 5.56B | 7.39B | |||||
EBITA | 6.44B | 3.1B | 6.46B | 5.38B | 7.16B | |||||
EBIT | 6.34B | 3.02B | 6.4B | 5.32B | 7.08B | |||||
EBITDAR | 6.57B | 3.27B | - | - | - | |||||
Effective Tax Rate - (Ratio) | 19.41 | 24.48 | 21.51 | 22.8 | 14.4 | |||||
Current Domestic Taxes | 1.19B | 968M | 1.5B | - | - | |||||
Total Current Taxes | 1.19B | 968M | 1.5B | 1.3B | 1.8B | |||||
Deferred Domestic Taxes | -45M | 7M | 15M | - | - | |||||
Total Deferred Taxes | -45M | 7M | 15M | -16M | -479M | |||||
Normalized Net Income | 3.16B | 2.92B | 4.83B | 3.34B | 5.81B | |||||
Interest on Long-Term Debt | 10M | 13M | 21M | 27M | 120M | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 661M | - | - | - | - | |||||
Research And Development Expense From Footnotes | 3.14B | 4.18B | 5.56B | 7.63B | 9.75B | |||||
Net Rental Expense, Total | 3M | 1M | - | - | - | |||||
Imputed Operating Lease Interest Expense | 960K | 280K | - | - | - | |||||
Imputed Operating Lease Depreciation | 2.04M | 720K | - | - | - | |||||
Stock-Based Comp., G&A Exp. (Total) | - | - | - | - | - | |||||
Stock-Based Comp., Other (Total) | 200M | 310M | 439M | 586M | 721M | |||||
Total Stock-Based Compensation | 200M | 310M | 439M | 586M | 721M |
- Stock Market
- Equities
- GMAB Stock
- Financials Genmab A/S
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















